Kanadische Plattform zur vergleichenden Wirksamkeit der Intensivpflege (CEPEC)
Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)
The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
- Arzneimittel: 1- Vasopressor - Mean arterial pressure 56-60
- Arzneimittel: 2- Vasopressor - Mean arterial pressure 61-65
- Arzneimittel: 3- Vasopressor - Mean arterial pressure 66-70
- Arzneimittel: 4- Vasopressor - Mean arterial pressure 71-75
- Sonstiges: 1- Platelet less than 10 x 109/L
- Sonstiges: 2- Platelet less than 20 x 109/L
- Sonstiges: 3- Platelet less than 30 x 109/L
- Sonstiges: 4- Platelet less than 40 x 109/L
- Sonstiges: 5- Platelet less than 50 x 109/L
- Sonstiges: Enteral nutrition - Boluses
- Sonstiges: Enteral nutrition - Continuous
Detaillierte Beschreibung
Many supportive therapies used daily in the ICU setting remain under-studied despite being resource-intensive. CEPEC aims to incorporate domains evaluating vasopressors and inotropes, nutrition, transfusions, sedation, correction of electrolyte deficits, sedation and analgesia, airway management, end-of-life care practices and other interventions.
Domains refer to categories of patient care for which interventions are being evaluated in a randomized controlled trial (RCT) within the platform.
VASOPRESSOR DOMAIN The investigators will investigate whether vasoactive medications should be used differently for different subgroups of patients who are in a state of cardiovascular shock (i.e. heterogeneity of treatment effects). Vasoactive medications are common in critically ill patients, and have considerable patient, hospital, and health system resource impact, but their use remains poorly supported by scientific evidence.
PLATELET DOMAIN Platelet transfusions are commonly prescribed to critically ill patients and have considerable patient, hospital, and health system resource impact, but remain poorly supported by scientific evidence. We propose to join a multicentre randomized clinical trial (T4P, ISRCTN79371664) addressing the optimal use of platelet transfusions for critically ill patients with thrombocytopenia in advance of invasive procedures. A multinational collaboration will ensure timely completion of this high-impact multicentre randomized clinical trial. The Canadian component of the T4P trial is embedded in the CEPEC platform as the Platelet Domain.
NUTRITION DOMAIN Most critically ill patients cannot eat normally and require a specialized method of feeding, called enteral nutrition. It is provided every hour around the clock. This differs from how we usually eat, with meals (boluses) divided over the day while we are awake. The goals of this study are to determine if a large study can be successfully done comparing nutrition given 3 times a day (boluses) compared to given in small amounts every hour (continuously).
INITIATIVES Initiatives are cross-cutting non-randomized studies nested within the platform that are relevant to all domains. Examples include a parallel observational study initiative, which aims to collect data about usual care and outcomes directly relevant to each domain. The goal is to describe the representativeness of domain results and to assess for protocol misalignment. Similarly, the living knowledge synthesis and health economics initiatives aim to generate meta-analyses and cost-effectiveness analyses alongside each trial conducted in the platform.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Marie-Helene Masse, RRT, MSc
- Telefonnummer: 14173 1-819-346-1110
- E-Mail: marie-helene.masse3@usherbrooke.ca
Studienorte
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 2Z3
- Rekrutierung
- Centre hospitalier universitaire Dr-Georges-L.-Dumont
-
Kontakt:
- Emma Boisvert
- Telefonnummer: 506-869-7391
- E-Mail: Emma.Boisvert@VitaliteNB.ca
-
Hauptermittler:
- Rémi Leblanc
-
-
Ontario
-
Brampton, Ontario, Kanada, L6R 3J7
- Rekrutierung
- William Osler Health System
-
Kontakt:
- Vinayak Lad
- Telefonnummer: 57517 905-494-2120
- E-Mail: vinayak.lad@williamoslerhs.ca
-
Hauptermittler:
- Alexandra Binnie
-
Hamilton, Ontario, Kanada, L8L 2X2
- Rekrutierung
- Hamilton General Hospital
-
Kontakt:
- Lori Hand
- Telefonnummer: 905-536-2777
- E-Mail: handlori@hhsc.ca
-
Hauptermittler:
- Kimia Honarmand
-
Hamilton, Ontario, Kanada, L8V 1C3
- Rekrutierung
- Hamilton Health Sciences - Juravinski Hospital
-
Kontakt:
- Tina Millen
- Telefonnummer: 905-521-2100
- E-Mail: millent@mcmaster.ca
-
Hauptermittler:
- Bram Rochwerg
-
Ottawa, Ontario, Kanada, K1H 8L6
- Rekrutierung
- The Ottawa Hospital
-
Kontakt:
- Irene Watpool
- Telefonnummer: 613-737-8724
- E-Mail: iwatpool@ohri.ca
-
Hauptermittler:
- Alexandre Tran
-
Scarborough Village, Ontario, Kanada, M1P 2V5
- Rekrutierung
- Scarborough Health Network
-
Kontakt:
- Joshua Craig
- Telefonnummer: 416-438-2911
- E-Mail: jcraig@shn.ca
-
Hauptermittler:
- Christopher Yarnell
-
St. Catharines, Ontario, Kanada, L2S 0A9
- Rekrutierung
- Niagara Health
-
Hauptermittler:
- Jennifer Tsang
-
Kontakt:
- Jennifer Tsang
- Telefonnummer: 905-684-7271
- E-Mail: jennifer.tsang@mail.utoronto.ca
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutierung
- Sunnybrook Health Sciences Centre
-
Kontakt:
- Nicole Marinoff
- Telefonnummer: 416-480-4522
- E-Mail: Nicole.Marinoff@sunnybrook.ca
-
Hauptermittler:
- Neill Adhikari
-
-
Quebec
-
Longueuil, Quebec, Kanada, J4V 2H1
- Rekrutierung
- Hôpital Charles-Le Moyne
-
Kontakt:
- Catherine Dubé
- Telefonnummer: 3605 450-466-5000
- E-Mail: catherine.dube.med@ssss.gouv.qc.ca
-
Hauptermittler:
- Dany Burke
-
Montreal, Quebec, Kanada, H2X 0C1
- Rekrutierung
- Centre hospitalier de l'Université de Montréal (CHUM)
-
Kontakt:
- Melissa Gagnon-Hamelin
- Telefonnummer: 31750 514 890-8000
- E-Mail: melissa.gagnon-hamelin.chum@ssss.gouv.qc.ca
-
Hauptermittler:
- Francois-Martin Carrier
-
Montreal, Quebec, Kanada, H4J 1C5
- Rekrutierung
- CIUSSS NIM - Hôpital du Sacré-Coeur-de-Montréal
-
Kontakt:
- Virginie Williams
- Telefonnummer: 1472 514-338-2222
- E-Mail: virginie.williams.cnmtl@ssss.gouv.qc.ca
-
Hauptermittler:
- Yiorgos Alexandros Cavayas
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutierung
- CIUSSS de l'Estrie - CHUS
-
Kontakt:
- Marie-Helene Masse, RRT, MSc
- Telefonnummer: 14173 819-346-1110
- E-Mail: marie-helene.masse3@usherbrooke.ca
-
Hauptermittler:
- Francois Lamontagne
-
Kontakt:
- Monica Sean, PhD
- Telefonnummer: 14266 819-346-1110
- E-Mail: monica.sean@usherbrooke.ca
-
-
-
-
-
Auckland, Neuseeland
- Noch keine Rekrutierung
- Auckland City Hospital
-
-
-
-
-
London, Vereinigtes Königreich
- Noch keine Rekrutierung
- Intensive Care National Audit and Research Centre (coordinating centre for sites in UK. Sites to be determined)
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.
Inclusion criteria:
- Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;
- MAP <75 mmHg at any point;
- Patient expected to be in the ICU for >24 hours.
Exclusion criteria:
- Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;
- Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);
- Acute subarachnoid hemorrhage (within 21 days);
- Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);
- Lung, heart, liver, kidney transplant recipient (within 7 days);
- Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);
- More than 24 hours since meeting inclusion criteria in the ICU;
- Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.
PLATELET DOMAIN
Inclusion criteria:
- Adult patients (age ≥18 years) admitted to the ICU;
- Latest platelet count in this hospital admission <50×109/L;
- Planned to undergo a specified low-moderate bleeding risk invasive procedure.
Exclusion criteria:
- Ongoing major hemorrhage requiring blood products and/or surgical/ radiological intervention;
- Intracranial hemorrhage within prior 72 hours;
- Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);
- Known advance decision of refusing blood/blood component transfusions;
- Acute promyelocytic leukemia (APML);
- Death perceived as imminent or admission for palliation;
- Previously randomized into the CEPEC Platelet Domain or the T4P Trial;
- Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.
NUTRITION DOMAIN
Inclusion criteria:
- Patient of ≥18 years of age;
- Patient is invasively mechanically ventilated (including endotracheal tube or tracheostomy);
- Orogastric/nasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);
- Treating team has started or has the intention of providing enteral nutrition.
Exclusion criteria:
- Patient who has had gastrointestinal (GI) surgery in the last 3 months and deemed not ready to receive possible bolus nutrition;
- Bowel obstruction or ischemia; active;
- Has a post-pyloric small bowel feeding tube;
- Active GI bleeding;
- Patient who is chronically receiving enteral nutrition.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Sonstiges: Vasopressor
Participants will receive vasopressor(s) and their mean arterial pressure will be titrated according to the group they are randomized to (group 1: 56-60 mmHg; group 2: 61-65 mmHg; group 3: 66-70 mmHg; group 4: 71-75 mmHg). Physicians will have the liberty of restricting the randomization to at least 2 contiguous ranges. |
Vasopressor(s) will be titrated according to 56-60 range. Vasopressor(s) will be titrated according to 61-65 range. Vasopressor(s) will be titrated according to 66-70 range. Vasopressor(s) will be titrated according to 71-75 range. |
|
Sonstiges: Platelet
Thrombocytopenic intensive care unit (ICU) patients (platelet count <50×109/L) with a planned low-moderate bleeding-risk procedure will be randomized to one of five equally spaced platelet thresholds (less than 10 x 109/L, less than 20 x 109/L, less than 30 x 109/L, less than 40 x 109/L, less than 50 X 109/L) below which they will receive prophylactic platelet transfusions before any low-moderate bleeding-risk procedure occurring during the ICU episode up to ICU day 90. Once randomized, the clinical team will administer a platelet transfusion according to the assigned threshold and the most recent platelet count at the time of the planned procedure. |
Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109/L at the time of the planned procedure. Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109/L at the time of the planned procedure. Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109/L at the time of the planned procedure. Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109/L at the time of the planned procedure. Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109/L at the time of the planned procedure. |
|
Sonstiges: Nutrition
The intervention is bolus feeding (given 3 times a day to meet nutritional targets) with formula type left to the discretion of the precribing team. With 2 hours between each "feed". The control is continuous feeding (over 24-hour period) with formula type left to the discretion of the prescribing team, which is the current standard of care. |
Given 3 times a day. Given over 24-hour period |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Platelet Domain - All cause mortality
Zeitfenster: 90 days
|
90-day all-cause mortality |
90 days
|
|
Nutrition Domain - Recruitment rate
Zeitfenster: 1 year
|
Recruitment rate of 2 patients per site per month. |
1 year
|
|
Vasopressor Domain - 30-day ordinal outcome
Zeitfenster: At hospital discharge up to day 30
|
Incorporate mortality, persistent organ dysfunction (POD) in the ICU, hospitalization, discharge to a location providing more health services than at the patient's baseline residence, and discharge to baseline level residence. |
At hospital discharge up to day 30
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Thrombozytendomäne - Mortalität bei der Entlassung aus dem Krankenhaus
Zeitfenster: Entlassung aus dem Krankenhaus
|
Entlassung aus dem Krankenhaus
|
|
|
Thrombozytendomäne - Mortalität nach 1 Jahr
Zeitfenster: 1 Jahr nach der Randomisierung
|
1 Jahr nach der Randomisierung
|
|
|
Thrombozytendomäne - Blutungen im Krankenhaus (Major und tödliche Blutungen)
Zeitfenster: Während des Krankenhausaufenthaltes
|
Während des Krankenhausaufenthaltes
|
|
|
Thrombozytendomäne - Tage lebendig und zu Hause am Tag 90 zu Hause
Zeitfenster: 90 Tage
|
90 Tage
|
|
|
Platelet Domain - Transfusion complications
Zeitfenster: During hospitalization
|
Transfusion-associated circulatory overload, transfusion-related acute lung injury, infections, anaphylaxis |
During hospitalization
|
|
Platelet Domain - Health-related quality of life
Zeitfenster: 90 days
|
Evaluated using EQ-5D-5L questionnaire |
90 days
|
|
Nutrition Domain - Diarrhea
Zeitfenster: 24 hours
|
Defined by the World Health Organization (WHO) definition (3 or greater liquids stools/24 hours) |
24 hours
|
|
Nutition Domain - Percentage of target nutritional intake
Zeitfenster: Over the course of the ICU stay up to day 30
|
>80% |
Over the course of the ICU stay up to day 30
|
|
Nutrition Domain - Vomiting
Zeitfenster: During ICU stay up to day 30
|
Vomiting 2 or more times in a 24-hour period |
During ICU stay up to day 30
|
|
Vasopressor, Platelet and Nutrition Domains - Each component of the 30-day ordinal primary outcome
Zeitfenster: At hospital discharge up to day 30
|
|
At hospital discharge up to day 30
|
|
Vasopressor, Platelet and Nutrition Domains - Days free of POD to day 30
Zeitfenster: At hospital discharge up to day 30
|
POD is defined as a vasopressor infusion, invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen (delivered via nasal prongs or cannula by a specialized device, with a FiO2 ≥0.4 and at a flow rate ≥30L/min), or new renal replacement therapy. |
At hospital discharge up to day 30
|
|
Vasopressor, Platelet and Nutrition Domains - Hospital days up to day 30
Zeitfenster: Up to day 30
|
Up to day 30
|
|
|
Vasopressor, Platelet and Nutrition Domains - ICU days to day 30
Zeitfenster: Up to day 30
|
Up to day 30
|
|
|
Platelet Domain - Number of days without POD in the ICU
Zeitfenster: Up to day 90
|
Up to day 90
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Francois Lamontagne, MD, MSc, Université de Sherbrooke
- Hauptermittler: Neill Adhikari, MDCM, MSc, Sunnybrook Research Institute
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- MP-31-2025-5600
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .